Home › Compare › EFTRW vs SCHD

EFTRW vs SCHD: Dividend Comparison 2026

EFTRW yields 333333.33% · SCHD yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EFTRW wins by $8.099219044190773e+31M in total portfolio value
10 years
EFTRW
EFTRW
● Live price
333333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.099219044190773e+31M
Annual income
$80,944,421,463,343,720,000,000,000,000,000,000,000.00
Full EFTRW calculator →
SCHD
Schwab U.S. Dividend Equity ETF
● Live price
3.44%
Share price
$30.68
Annual div
$1.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$422.61
Full SCHD calculator →

Portfolio growth — EFTRW vs SCHD

📍 EFTRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEFTRWSCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EFTRW + SCHD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EFTRW pays
SCHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFTRW
Annual income on $10K today (after 15% tax)
$28,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr
SCHD
Annual income on $10K today (after 15% tax)
$292.49/yr
After 10yr DRIP, annual income (after tax)
$359.22/yr
At 15% tax rate, EFTRW beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFTRW + SCHD for your $10,000?

EFTRW: 50%SCHD: 50%
100% SCHD50/50100% EFTRW
Portfolio after 10yr
$4.0496095220953863e+31M
Annual income
$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr
Blended yield
99.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EFTRW right now

EFTRW
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-13.6
Piotroski
2/9
SCHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFTRW buys
0
SCHD buys
0
No recent congressional trades found for EFTRW or SCHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEFTRWSCHD
Forward yield333333.33% ✓3.44%
Annual dividend / share$2.00 ✓$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$8.099219044190773e+31M$29.0K ✓
Annual income after 10y$80,944,421,463,343,720,000,000,000,000,000,000,000.00 ✓$422.61
Total dividends collected$8.098906375781879e+31M ✓$3.9K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: EFTRW vs SCHD ($10,000, DRIP)

YearEFTRW PortfolioEFTRW Income/yrSCHD PortfolioSCHD Income/yrGap
1← crossover$33,344,033$33,333,333.33$11,224$344.10+$33.33M → EFTRW
2$103,911,171,366$103,875,493,250.26$12,567$354.98+$103911.16M → EFTRW
3$302,644,656,190,810$302,533,471,237,448.00$14,038$365.30+$302644656.18M → EFTRW
4$823,817,797,451,856,400$823,493,967,669,732,100.00$15,648$375.06+$823817797451.84M → EFTRW
5$2,095,836,995,961,804,000,000$2,094,955,510,918,530,000,000.00$17,410$384.27+$2095836995961804.00M → EFTRW
6$4,983,251,920,823,462,000,000,000$4,981,009,375,237,783,000,000,000.00$19,335$392.95+$4983251920823461888.00M → EFTRW
7$11,073,835,968,753,321,000,000,000,000$11,068,503,889,198,040,000,000,000,000.00$21,437$401.10+$1.1073835968753322e+22M → EFTRW
8$22,999,277,308,531,336,000,000,000,000,000$22,987,428,304,044,770,000,000,000,000,000.00$23,733$408.75+$2.2999277308531335e+25M → EFTRW
9$44,643,905,199,991,210,000,000,000,000,000,000$44,619,295,973,271,085,000,000,000,000,000,000.00$26,237$415.91+$4.464390519999121e+28M → EFTRW
10$80,992,190,441,907,720,000,000,000,000,000,000,000$80,944,421,463,343,720,000,000,000,000,000,000,000.00$28,968$422.61+$8.099219044190773e+31M → EFTRW

EFTRW vs SCHD: Complete Analysis 2026

EFTRW — Stock

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Full EFTRW Calculator →

SCHD — ETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →
📬

Get this EFTRW vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFTRW vs JEPIEFTRW vs OEFTRW vs KOEFTRW vs MAINEFTRW vs VYMEFTRW vs DGROEFTRW vs VIGEFTRW vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.